A subanalysis of the NOAH-AFNET 6 trial showed that patients who have had a stroke and were treated with oral anticoagulation with edoxaban did not have a reduced risk of a second stroke compared to those not receiving anticoagulation. Additionally, the risk of major bleeding was more than quadruple in those receiving anticoagulation. However, patients with a low atrial fibrillation burden were found to have a low stroke rate. This research is changing the paradigm for anticoagulation in patients with stroke, requiring a more individualized approach to balance the risk of stroke and bleeding. More research is needed to better understand AF characteristics and stroke risk.
Source link
Anticoagulation Shows No Benefit in Preventing Second Stroke
